Zolmitriptan intranasal - Shin Nippon Biomedical Laboratories

Drug Profile

Zolmitriptan intranasal - Shin Nippon Biomedical Laboratories

Alternative Names: TRZ

Latest Information Update: 22 Mar 2016

Price : $50

At a glance

  • Originator Shin Nippon Biomedical Laboratories
  • Class Antimigraines; Oxazolidinones; Small molecules; Tryptamines
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Migraine

Most Recent Events

  • 22 Mar 2016 Intranasal zolmitriptan is still in phase I development for acute Migraine in USA
  • 08 Oct 2013 Intranasal zolmitriptan is still in phase I development for acute Migraine in USA
  • 04 Apr 2012 Adverse events and pharmacokinetics data from a phase I trial in healthy volunteers released by Shin Nippon Biomedical Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top